Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Japan Pharma Market Hits 11.5 Trillion Yen in 2024, Keytruda Wins Crown: IQVIA
March 5, 2025
- 680 Employees Exit Takeda in Buyout Program, 10%-Plus of Japan Staff
March 4, 2025
- Novartis Bags Global Rights to Kyorin’s MRGPRX2 Antagonist
March 4, 2025
- Australia Rejects Lecanemab Again, Eisai to Challenge Decision
March 4, 2025
- Blackstone to Buy 60% Stake in Japan CRO CMIC
March 4, 2025
- Alfresa to Build New Cell Therapy CDMO Site in Japan
March 4, 2025
- ASKA Ties Up with Philippines’ MedChoice in Thyroid Space
March 4, 2025
- Japan’s 1st CGP Assay for Blood Cancer Now Available: Otsuka
March 4, 2025
- Enhertu Gets EMA Backing for HER2-Low/Ultralow Breast Cancer
March 4, 2025
- Nxera Assigns Cenerimod Rights in Japan, APAC to Viatris
March 3, 2025
- Ono to Consolidate US, European Operations to Deciphera
March 3, 2025
- Over 60% of Doctors Have Prejudices about Obesity: Lilly/Mitsubishi Survey
March 3, 2025
- GSK Vows to Ensure Proper Use of Shingles Jab towards NIP Inclusion
March 3, 2025
- Eisai Licenses Tasfygo to SciClone in Greater China Region
March 3, 2025
- Chiome Inks Research Collab Pact with OmniAb
March 3, 2025
- Cariprazine Broadens Label in Thailand: Mitsubishi Tanabe
March 3, 2025
- 2-Dose Vial of COVID Vaccine Filed in Japan: Meiji
March 3, 2025
- Higher-Dose Regimen of Spinraza Filed in Japan: Biogen
March 3, 2025
- Some Generics See Lower Profit Margins, Return to LLPs after Elective Care Rollout
February 28, 2025
- FRONTEO to Provide AI-Based Drug Discovery Support Service in US
February 28, 2025
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…